Compounding pharmacies in Oregon
By the PeptideAgent Editorial Team. Editorially reviewed, not clinically reviewed. Last verified
The Oregon Board of Pharmacy regulates compounding pharmacies in Oregon. Compounded GLP-1 limited. How to check a pharmacy's license, plus listings with their verification status.
Oregon at a glance
- Pharmacy regulator
- Oregon Board of Pharmacy
- 503A framework
- Follows the federal 503A framework
- Telehealth prescribing
- Regulatory: Telehealth allowed
- Asynchronous prescribing
- Regulatory: Async allowed
- Compounded GLP-1 access
- Regulatory: Compounded GLP-1 limited
Compounding pharmacies serving Oregon
No verified compounding pharmacies serving Oregon are listed yet. A provider appears here only after it passes the verification checklist, and those checks are still under way.
Looking for care now? Start with what the law allows where you live, then how a legitimate prescription works.
Run a pharmacy, clinic, or telehealth service? Apply for a listing.
Who regulates compounding pharmacies in Oregon
The Oregon Board of Pharmacy registers drug outlets under ORS chapter 689: ORS 689.005 defines a drug outlet to include any establishment with facilities located within or out of Oregon that dispenses or delivers drugs in Oregon, and ORS 689.305 requires all drug outlets to register annually. OAR 855-041-1060 requires every non-resident pharmacy that provides drugs or services to a person in Oregon to register with the Board, to be registered in its home state, and to designate an Oregon-licensed pharmacist-in-charge. Compounding is governed by OAR chapter 855, division 183 (Drug Compounding), adopted effective June 17, 2026 in place of the former division 45. OAR 855-183-0001 applies the division to sterile and non-sterile compounding and requires any entity inside or outside Oregon that compounds for dispensing or delivery in Oregon to register as a drug outlet; OAR 855-183-0015 requires compliance with USP chapters 795, 797, and 800 and, from November 1, 2027, requires non-resident outlets that compound to show home-state inspection against current USP standards or an approved accreditation. Oregon has not created a state bulks list; eligibility follows the federal 503A framework (approved drug component, USP or NF monograph, or FDA 503A bulks list). [1] [2] [3] [4] [6]
Compounded GLP-1 access in Oregon
Telehealth GLP-1 patients should confirm the dispensing pharmacy appears in the Board of Pharmacy license lookup. [1] [9]
Research use only sellers in Oregon
ORS chapter 689 restricts dispensing of prescription drugs to registered pharmacies and licensed practitioners, and a seller of "research use only" injectable peptides to Oregon consumers is not a registered drug outlet. Oregon's Unlawful Trade Practices Act, ORS 646.608(1)(e), makes it unlawful in the course of business to represent that goods have characteristics, uses, or benefits that they do not have. [2] [5] [10]
How to check a compounding pharmacy in Oregon
- Search the Oregon Board of Pharmacy license lookup for the pharmacy by name. A pharmacy based elsewhere needs whatever license or registration Oregon requires before it ships to you. [1] [2] [3] [4] [6]
- Ask whether it operates as a 503A pharmacy or a 503B outsourcing facility, and confirm a 503B claim against FDA's outsourcing facility information (see the verification checklist).
- Confirm the peptide can be lawfully compounded: check its status on the regulatory tracker or its peptide page before paying.
- Walk away from any seller that labels a peptide "research use only" or "not for human consumption". See the research use only section above for what that means in Oregon. [2] [5] [10]
Common questions in Oregon
How do I check whether a mail-order pharmacy can ship compounded peptides to Oregon?
Search the Oregon Board of Pharmacy license lookup for the pharmacy. Under ORS 689.305 and OAR 855-041-1060 an out-of-state pharmacy must register with the Board as a non-resident pharmacy before shipping to Oregon patients. If the pharmacy is not listed, the shipment is not lawful in Oregon even if the prescriber is compliant. [1] [2] [3]
Can an Oregon pharmacy compound BPC-157 or other unapproved peptides?
Only under a draft federal policy, and only within strict limits. On October 28, 2026 HHS released a draft enforcement discretion policy saying it will not take enforcement action against a state-licensed pharmacy that compounds BPC-157 as a single-ingredient product by an allowed route, on a patient-specific prescription, from an FDA-registered manufacturer's substance with a tested certificate of analysis, with serious adverse events reported to FDA. BPC-157 is still not FDA approved or on the 503A bulks list, the policy is not binding and HHS may revisit it, and blends such as Wolverine are not covered. FDA's drug center recommended against listing BPC-157; the advisory committee voted in favor (HHS policy, Appendix B). The draft covers only six single peptides (BPC-157, epitalon, KPV, MOTS-c, semax, TB-500); others, such as CJC-1295 and ipamorelin, are not covered. State law still applies: Oregon has not created a state bulks list; eligibility follows the federal 503A framework. [4] [7] [8] [11] [12]
Sources
- [1]Oregon Board of Pharmacy
- [2]ORS chapter 689, Pharmacists; Drug Outlets; Drug Sales
- [3]Oregon Administrative Rule 855-041-1060, Non-Resident Pharmacies
- [4]Oregon Administrative Rules chapter 855, division 183, Drug Compounding (Oregon Board of Pharmacy, effective June 17, 2026)
- [5]ORS 646.608, Additional unlawful business, trade practices (Unlawful Trade Practices Act)
- [6]FDA: Section 503A of the Federal Food, Drug, and Cosmetic ActFDA
- [7]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (503A and 503B category lists)FDA
- [8]FDA: Pharmacy Compounding Advisory CommitteeFDA
- [9]FDA: concerns with unapproved GLP-1 drugs used for weight loss, including shortage resolution and compounding grace periodsFDA
- [10]21 U.S.C. 331, Prohibited acts
- [11]Federal Register notice of availability: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496)Federal Register, 2026
- [12]HHS: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (draft, with Appendix A and Appendix B)2026